



# Pulmonary Artery Catheterization & Cardiogenic Shock: Part 1

*BWH Housestaff Noon Conference*

*August 14, 2024*

Marc S. Sabatine, MD, MPH

Chair, TIMI Study Group

Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine

Professor of Medicine, Harvard Medical School





# Disclosures

---

## **Research Grant Support through BWH:**

Abbott; Amgen; Anthos Therapeutics; AstraZeneca; Boehringer Ingelheim; Daiichi-Sankyo; Ionis; Merck; Novartis; Pfizer; Saghmos Therapeutics; Verve Therapeutics

## **Scientific Advisory Boards & Consulting:**

Amgen; AMPEL BioSolutions; Anthos Therapeutics; AstraZeneca; Boehringer Ingelheim; Dr. Reddy's Laboratories





# Shock

---

---

**“State of cellular and tissue hypoxia due to either  
↓ O<sub>2</sub> delivery, ↑ O<sub>2</sub> consumption,  
inadequate O<sub>2</sub> utilization,  
or a combination of these processes.”**





# Types of Shock

Type	PCWP	CO	SVR
Hypovolemic			
Cardiogenic			
Distributive			





# Types of Shock

Type	PCWP	CO	SVR
Hypovolemic	↓↓	↓	↑
Cardiogenic			
Distributive			





# Types of Shock

Type	PCWP	CO	SVR
Hypovolemic	↓↓	↓	↑
Cardiogenic	↑	↓↓	↑
Distributive			





# Types of Shock

Type	PCWP	CO	SVR
Hypovolemic	↓↓	↓	↑
Cardiogenic	↑	↓↓	↑
Distributive	↔ or ↓	Var	↓↓





# Types of Shock (2.0)

Type		RA	PCWP	CO	SVR
<b>Hypovolemic</b>		↓↓	↓↓	↓	↑
<b>Cardiogen.</b>	<b>Left-sided</b>	↔ or ↑	↑	↓↓	↑
	<b>Right-sided</b>	↑	↔ or ↓		
	<b>Biventricular</b>	↑	↑		
<b>Mixed</b>		↑	↑	↓↓	↓↓
<b>Distributive</b>		↔ or ↓	↔ or ↓	<b>Var</b>	↓↓
<b>Obstruct.</b>	<b>Tension PTX</b>	↓↓	↓	↓↓	↑
	<b>PE</b>	↑	↓		
	<b>Tamponade</b>	↑	↑		







# Definition of Cardiogenic Shock

- **Complex clinical syndrome characterized by clinical triad of:**
  - 1) **Tissue and organ hypoperfusion** →  $\Delta$  mental status, cool or mottled extremities, oliguria, ischemic liver or kidney injury, lactic acidosis
  - 2) **Ineffective cardiac output** (clinical assessment or invasive hemodynamics)
  - 3) **Normal or elevated cardiac filling pressures** (pulmonary congestion seen in ~2/3)
- Clinical trial entry criteria generally include sustained HoTN, but “normotensive CS” can occur (~5%) in setting of intense vasoconstriction
- **Hemodynamic criteria:**
  - CI <2.2 L/min/m<sup>2</sup>
  - PCWP >15 mmHg





# Assessing Shock

Type	Invasive	Non-Invasive
Perfusion pressure	Arterial line	
Filling Pressures	Left-sided: PCWP from PAC Right-sided: RA (or CVP from CVC)	
Cardiac Output	Thermodilution or Fick CO from PAC (can approx. w/ $S_{cv}O_2$ from CVC)	
SVR	Calculated from MAP, CVP & CO	





# Assessing Shock

Type	Invasive	Non-Invasive
Perfusion pressure	Arterial line	Sphygmomanometer
Filling Pressures	Left-sided: PCWP from PAC Right-sided: RA (or CVP from CVC)	
Cardiac Output	Thermodilution or Fick CO from PAC (can approx. w/ $S_{cv}O_2$ from CVC)	
SVR	Calculated from MAP, CVP & CO	





# Assessing Shock

Type	Invasive	Non-Invasive
Perfusion pressure	Arterial line	Sphygmomanometer
Filling Pressures	Left-sided: PCWP from PAC Right-sided: RA (or CVP from CVC)	Left-sided: (cardiogenic) pulmonary edema (not always apparent in chronic HF), S <sub>3</sub> R-sided: JVP; periph edema & ascites (not acutely; affected by oncotic P)
Cardiac Output	Thermodilution or Fick CO from PAC (can approx. w/ S <sub>cv</sub> O <sub>2</sub> from CVC)	
SVR	Calculated from MAP, CVP & CO	





# Assessing Shock

Type	Invasive	Non-Invasive
Perfusion pressure	Arterial line	Sphygmomanometer
Filling Pressures	Left-sided: PCWP from PAC Right-sided: RA (or CVP from CVC)	Left-sided: (cardiogenic) pulmonary edema (not always apparent in chronic HF), S <sub>3</sub> R-sided: JVP; periph edema & ascites (not acutely; affected by oncotic P)
Cardiac Output	Thermodilution or Fick CO from PAC (can approx. w/ S <sub>cv</sub> O <sub>2</sub> from CVC)	UOP (not if other cause of AKI); LFTs, lactate; pulse pressure; mental status
SVR	Calculated from MAP, CVP & CO	





# Assessing Shock


Type	Invasive	Non-Invasive
Perfusion pressure	Arterial line	Sphygmomanometer
Filling Pressures	Left-sided: PCWP from PAC Right-sided: RA (or CVP from CVC)	Left-sided: (cardiogenic) pulmonary edema (not always apparent in chronic HF), S <sub>3</sub> R-sided: JVP; periph edema & ascites (not acutely; affected by oncotic P)
Cardiac Output	Thermodilution or Fick CO from PAC (can approx. w/ S <sub>cv</sub> O <sub>2</sub> from CVC)	UOP (not if other cause of AKI); LFTs, lactate; pulse pressure; mental status
SVR	Calculated from MAP, CVP & CO	Capillary refill; forearm & leg temperature





# RAP vs. PCWP in *Chronic HF*

1000 Patients with Chronic HF Evaluated at Transplant Center w/ PAC





		PCWP	
		<22	≥22
RAP	<10	~30%	~15%
	≥10	~6%	~49%

- *If RAP high, WP very likely high*
- *If RAP low, WP still high in ~1/3 of cases*





# CVP vs. PCWP in *Acute MI*



Forrester et al. *NEJM* 1971;285:190







# Oxygen Saturation in Shock

Situation	CVO <sub>2</sub> vs. MVO <sub>2</sub>	Correlation	
		Absolute	Δs
Normal	CVO <sub>2</sub> 2-3% lower	n/a	n/a
Shock	CVO <sub>2</sub> ~6±6% <u>higher</u>	0.89	n/a
Cardiogenic Shock	CVO <sub>2</sub> ~10±10% <u>higher</u>	0.55	0.92


↓ splanchnic blood flow →  
↑ O<sub>2</sub> extraction → ↓ IVC O<sub>2</sub> sat





# Lewis Dexter, MD

- Born in Boston
- Harvard (1932), HMS (1936)
- Residency at Presbyterian
- Returned to Boston to study w/ Soma Weiss
- Went to Buenos Aires to study hypertension w/ Bernardo Houssay (who would go on to receive Nobel Prize)
- Returned to Boston, continued his research under Soma Weiss (now at Peter Bent Brigham) to study renin





# 1<sup>st</sup> Catheterization of Pulmonary Artery

---



- On Dec 7, 1944, catheterizing renal vein of a patient w/ HTN under fluoro
- “I decided to wander around the heart ... Suddenly, this catheter came clear out in the lung field and I was sure I [had] perforated the heart. I didn’t have any idea what to do ...”
- I turned on the overhead lights and said, “Mr. S\_\_\_\_, how are you?”
- He said, “I feel a hell of a lot better than you look.”
- “I went and looked up the anatomy of the chest and I figured I had gone into the pulmonary artery.”
- Later that day, discussed with HMS Dean Charles Burwell (a cardiologist), who remarked that if he could do it again, could study congenital heart disease, which Dexter went on to do.





# Balloon Flotation PAC

- “I had had a very difficult evening with a very sick lady and failed completely to advance [the PA] catheter.
- The next day I was watching my kids at the beach and there was a sailboat on an apparently calm sea and it had a big spinnaker out in front of it.
- So, I thought well now probably the answer is to have a propulsion mechanism. A sail ... or something like that ....
- And stick that on the end of a flexible catheter and that would work.”




William Ganz and H.J.C. Swan

*Jeremy Swan, MD*






# Pulmonary Artery Catheter





# PAC Waveforms



**Right  
Atrium  
(RA)**


Upper limits  
of normal  
(mmHg)

**6**






# LA, LV, and Aortic pressures





# PAC Waveforms








# Pulm Capillary Wedge Pressure

When balloon inflated, static column of blood between distal pulmonary artery and distal pulmonary vein.  
No flow,  $\therefore$  pressures should be equivalent.




Modified from eMedicine.com





# What value best represents LV preload?





# Preload

## Length-Tension Relationship in Myocytes



## Frank-Starling Curve in Heart




Braunwald's  
Heart Disease  
4/e

Cardiac Output (L/min)

LV Stroke Volume

Target preload to:  
1) Optimize LV performance (CO), while  
2) Minimizing risk of pulmonary edema




LV end-diastolic Volume

LVEDP or PCWP (mmHg)




# What value best represents LV preload?





# Pulm Capillary Wedge Pressure

When balloon inflated, static column of blood between distal pulmonary artery and distal pulmonary vein.  
No flow,  $\therefore$  pressures should be equivalent.




Modified from eMedicine.com

- $\therefore$  PCWP
- $\approx$  pulm vein pressure
- $\approx$  LA pressure
- $\approx$  LV EDP
- $\propto$  LV EDV or preload



# PCWP vs. Preload

When balloon inflated, static column of blood between distal pulmonary artery and distal pulmonary vein.  
No flow,  $\therefore$  pressures should be equivalent.




Modified from eMedicine.com

$\therefore$  PCWP  
 $\approx$  pulm vein pressure  
*but not if pulm vv stenosis*  
 $\approx$  LA pressure  
*but not if MV disease*  
 $\approx$  LV EDP  
 $\Delta$ 'd if LV less compliant  
 $\propto$  LV EDV or preload



# What is the Wedge

*Spontaneously breathing patient w/o pulmonary disease*





# Intracardiac Pressures & Phases of Respiration

---

## *Inspiration, Expiration, or Average?*

- Measured pressure relative to atmospheric pressure
- Heart sits inside pericardium within the thoracic cavity
- Want to read pressures when intrathoracic pressure closest to 0
- By convention, use end-expiration
- Spont breathing Pts: PCWP expiration > inspiration
- Ventilated Pts: PCWP expiration *usually* < inspiration








# Read PCWP at End-Expiration

*Spontaneously breathing patient w/o pulmonary disease*





# Calculating Cardiac Output

## Thermodilution

- Application of indicator-dilution method
- Inject cold solution into RA (or heating element on PAC for CCO)
- Measure temperature at PA
- Generate a thermodilution curve
- CO inversely proportion to AUC

## Fick

- $O_2$  consumption = CO  $\times$  AV  $O_2$  difference

$$CO = \frac{O_2 \text{ consumption}}{AV O_2 \text{ diff}}$$




Estimated using this # for every Pt in ICU ...

125 mL/min/m<sup>2</sup>

$$CO = \frac{125 \text{ mL/min/m}^2}{Hb \times 10 \times 1.36 \times [\text{arterial } O_2 \text{ sat} - \text{mixed venous } O_2 \text{ sat}]}$$

Usually only value that is significantly  $\Delta$ 'ing





# Mixed Venous O<sub>2</sub> Sat

Value (%)	Status
65-80	Normal; $DO_2 \geq VO_2$





# Mixed Venous O<sub>2</sub> Sat

Value (%)	Status
65-80	Normal; $DO_2 \geq VO_2$
50-65	↑ O <sub>2</sub> extraction to compensate for ↓ $DO_2$ or ↑ $VO_2$
30-50	Exceeding max O <sub>2</sub> extraction; $VO_2 > DO_2$ ; beginning of anaerobic metabolism & lactic acidosis
<30	Severe lactic acidosis & cellular death





# Mixed Venous O<sub>2</sub> Sat

Value (%)	Status
>80	
65-80	Normal; $DO_2 \geq VO_2$
50-65	↑ O <sub>2</sub> extraction to compensate for ↓ $DO_2$ or ↑ $VO_2$
30-50	Exceeding max O <sub>2</sub> extraction; $VO_2 > DO_2$ ; beginning of anaerobic metabolism & lactic acidosis
<30	Severe lactic acidosis & cellular death





# Mixed Venous O<sub>2</sub> Sat

Value (%)	Status
>80	↓↓ VO <sub>2</sub> (eg, sepsis w/ impaired extraction, hypothermia, cyanide) Shunt: L→R intracardiac shunt; large peripheral AV fistula Wedged sat (sampling pulm vv blood); ? torrential MR ↑↑ DO <sub>2</sub>
65-80	Normal; DO <sub>2</sub> ≥ VO <sub>2</sub>
50-65	↑ O <sub>2</sub> extraction to compensate for ↓ DO <sub>2</sub> or ↑ VO <sub>2</sub>
30-50	Exceeding max O <sub>2</sub> extraction; VO <sub>2</sub> > DO <sub>2</sub> ; beginning of anaerobic metabolism & lactic acidosis
<30	Severe lactic acidosis & cellular death





# Afterload or Vascular Resistance

---

- Ohm's law: **V** (voltage) = **I** (current) × **R** (resistance)
- Applied to the heart: Pressure gradient = CO × Vascular Resistance  
Vascular Resistance = Pressure gradient / CO
- Not directly measured, but calculated
- For systemic circulation:  $SVR = (MAP - RA) / CO$
- For pulmonary circulation:  $PVR = (\text{mean PA} - WP) / CO$





# Utility of SVR & PVR

- **SVR**: usually obvious in isolated septic shock (patient warm, CO high, MAP low,  $\therefore$  SVR low)

Can be useful to clarify mixed picture (low CO with concomitant vasoplegia)

- **PVR**: can differentiate  $\uparrow$  pulm pressures due to intrinsic pulm vasc disease (1 $^{\circ}$  PHT or PAH) vs. backward transmission of left-sided heart failure
  - $PVR = (\text{mean PA} - WP) / CO$
  - If transpulmonary gradient (mean PA – WP)  $\leq 12$  mmHg, or diastolic gradient (PA diastolic – WP)  $< 7$  mmHg, then numerator will be small, and  $\therefore$  PVR unlikely to be elevated







# Measurement Error

<b>Parameter</b>	<b>Error</b>
<b>PCWP</b>	<b><math>\pm 4</math> mmHg</b>
<b>Thermodilution CO</b>	<b><math>\pm 0.5</math> L/min</b>
<b>MVO<sub>2</sub></b>	<b><math>\pm 2</math> %</b>





# Indications of PAC

---

- **Diagnosis & evaluation**

- Ddx shock (especially if empiric therapy failed or high risk)
- Quantify cardiac filling pressures or aid in Ddx pulmonary edema (especially if trial of diuretic failed)
- Assess mechanical complications of acute MI
- Quantify CO, degree of pulmonary hypertension

- **Treatment**

- Tailored Rx in cardiogenic shock to optimize cardiac parameters
- Guide vasodilator Rx in PHT






# Forward vs. Backward Failure

200 Pts w/ Acute Q-wave MI

		Congestion		
		No	Yes	
Hypoperfusion	No	75	36	111
	Yes	22	67	89
		97	103	200






# Forward vs. Backward Failure

200 Pts w/ Acute Q-wave MI

		Congestion		
		No	Yes	
Hypoperfusion	No	75	36	111
	Yes	22	67	89
		97	103	200



25-33% of Pts with hypoperfusion / low CI do not have congestion / high WP





# Major Randomized Trials of PAC

Trial				Result
SVO <sub>2</sub> Collab (NEJM '95)				
Canadian Crit Care (NEJM '03)				
French PAC (JAMA '03)				
PAC-Man (JAMA '03)				
FACTT (NEJM '06)				





# Major Randomized Trials of PAC

Trial				Result
SVO <sub>2</sub> Collab (NEJM '95)				No $\Delta$ in mortality
Canadian Crit Care (NEJM '03)				No $\Delta$ in mortality
French PAC (JAMA '03)				No $\Delta$ in mortality
PAC-Man (JAMA '03)				No $\Delta$ in mortality
FACTT (NEJM '06)				No $\Delta$ in mortality





# Major Randomized Trials of PAC

Trial	Subjects	Baseline Char	Intervention	Result
SVO <sub>2</sub> Collab (NEJM '95)	Surgery, trauma, sepsis, bleed	PCWP 14 CI 3.7 MVO <sub>2</sub> 68%	All PAC; CI >4.5 vs. MVO <sub>2</sub> ≥70% vs. std care	No Δ in mortality
Canadian Crit Care (NEJM '03)	Surgery	CVP ~10 CI ~2.8	Routine PAC w/ goal CI 3.5-4.5 vs. Ø PAC; ~1/2 got colloid or PRBCs	No Δ in mortality
French PAC (JAMA '03)	Shock, ARDS; Ø AMI, ~6% cardiogenic	n/a	PAC vs. Ø PAC; no therapeutic protocol	No Δ in mortality
PAC-Man (JAMA '03)	ICU; ~11% decomp HF	n/a	PAC vs. Ø PAC; no therapeutic protocol; most common Δ after PAC was IVF	No Δ in mortality
FACTT (NEJM '06)	ALI 5L fluid pre-rand	CVP ~12 PCWP ~15	PAC vs. CVC; therapeutic protocol; net +3 L; dobuta <10%	No Δ in mortality





# Major Randomized Trials of PAC




Trial	Subjects	Baseline Char	Intervention	Result
ESCAPE (JAMA '05)	Decomp HF; but not cardio shock, excluded if: dopa (>3 $\mu\text{g}/\text{kg}/\text{min}$ ), dobuta (>3), or milrinone	PCWP 25 CI 1.9 SBP 106 SVR 1500	PAC vs. $\emptyset$ PAC; goal RAP $\leq 8$ & PCWP $\leq 15$ ; inotropes discouraged; vasodil 37 vs 19% inotropes 44 vs 39%	No $\Delta$ in mortality







# Critical Care Cardiology Trial Network





# Take Home Points

---

---

- **Consider if Pt in cardiogenic shock (can be normotensive)**
- **Use clues from physical exam**
- **Consider PAC for patients w/ acute MI or decompensated HF in cardiogenic shock or not responding to initial Rx for hypotension/congestion**
- **Study the waveforms carefully**
- **Filling pressures (PCWP)**
  - Ensure assumptions linking PCWP to LV preload are true
  - Think about what you want to learn from PCWP (preload; pulmonary edema)
- **Cardiac output: thermodilution vs. Fick (assumptions for each)**
- **Trends are more valuable than isolated data points**

